Octagon Capital Advisors’s ArriVent BioPharma AVBP Stock Holding History

Octagon Capital Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.5M	Hold	1,971,054	–	–	5.03%	6
2025 Q4	$39.7M	Hold	1,971,054	–	–	4.81%	7
2025 Q3	$36.4M	Buy	1,971,054 +25,000	+1%	+$491K	5.51%	5
2025 Q2	$42.4M	Sell	1,946,054 -113,333	-6%	-$2.35M	9.3%	2
2025 Q1	$38.1M	Hold	2,059,387	–	–	7.37%	4
2024 Q4	$54.9M	Buy	2,059,387 +83,000	+4%	+$2.38M	9.03%	2
2024 Q3	$46.4M	Buy	1,976,387 +173,083	+10%	+$3.93M	7.22%	5
2024 Q2	$33.5M	Sell	1,803,304 -140,532	-7%	-$2.51M	5.26%	6
2024 Q1	$34.7M	Buy	+1,943,836	New	+$39.2M	4.16%	6

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCGM

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Octagon Capital Advisors's AVBP Position: Q1 2026 in Review

Octagon Capital Advisors held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 1,971,054 shares worth $45.5M. The position accounts for 5.03% of the portfolio, ranked #6.

Octagon Capital Advisors first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $54.9M in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Octagon Capital Advisors held 1,971,054 shares of ArriVent BioPharma worth $45.5M as of Q1 2026.
Octagon Capital Advisors left its ArriVent BioPharma share count unchanged in Q1 2026.
ArriVent BioPharma made up 5.03% of Octagon Capital Advisors's portfolio in Q1 2026, its #6 holding.
Octagon Capital Advisors first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
Octagon Capital Advisors's ArriVent BioPharma position peaked at $54.9M in Q4 2024.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.